Astorg takes majority stake in Ethypharm
Context
Astorg Partners has entered into a definitive agreement to acquire a 60% majority stake in Ethypharm. The transaction follows a competitive sale process that included both industrial players and other private equity funds. The operation marks a resolution to a long-standing governance conflict between the laboratory's founding shareholders. Under the new ownership structure, the management team and current CEO will retain approximately 29% of the capital, while Intermediate Capital Group (ICG) and other minor shareholders will hold the remaining balance. The strategic rationale for the acquisition is to support Ethypharm’s transition from a primarily European player into a global leader in sophisticated galenic forms. Astorg Partners intends to accelerate the laboratory's development in North America, specifically targeting acquisitions to gain a local foothold in that market. The investment aims to capitalize on the target's strong historical growth rate and its specialized technical capabilities. The management team will remain in place to ensure operational continuity and execute the internationalization strategy, focusing on scaling the company’s R&D-driven business model while maintaining its established production excellence in Europe and Asia.
Ethypharm, which reported an EBITDA margin of [members only] in 2007, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Headquartered in Saint-Cloud, Ethypharm is a specialized pharmaceutical group focused on the development and manufacturing of drug delivery systems and galenic forms. The entity maintains a strong therapeutic focus on the central nervous system, particularly in the treatment of pain and addiction, which accounts for nearly half of its total revenue. The business model is built on high-value clinical differentiation and an extensive international reach, with 66% of its commercial activity generated outside of France. The company operates through a global network of over 80 partners and maintains direct subsidiaries in key markets including the United States, Canada, the United Kingdom, Germany, and China. Historically, the firm has strengthened its portfolio through strategic acquisitions, such as Laboratoires Pharmaceutiques Dexo and the British specialist DB Ashbourne. Its value proposition centers on its specialized R&D capabilities and complex manufacturing processes that cater to global pharmaceutical standards.
Ent. Value
€300–700M
Equity Value
[members only]
Multiples
EV / Revenue
1x–3x
EV / EBITDA
10x–18x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with Ethypharm
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2016 | PAI PARTNERS | ETHYPHARM | FRANCE | Pharma & Biotech |
Other operations with Astorg
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2021 | ASTORG | XCEPTOR | UNITED KINGDOM | Financial Services / Banking |
| 06/2020 | ASTORG | NORMEC | NETHERLANDS | TIC (Testing, Inspection, Certification) |
| 04/2020 | CINVEN / ASTORG | LGC GROUP | UNITED KINGDOM | TIC (Testing, Inspection, Certification) |
| 02/2019 | ASTORG | ANAQUA | UNITED STATES | Industry-Specific Software |
| 10/2018 | ASTORG | NEMERA | FRANCE | Medical Consumables |
| 04/2016 | ASTORG | FLOWBIRD (EX PARKEON) | FRANCE | Industry-Specific Software |
| 02/2016 | ASTORG / GOLDMAN SACHS | HRA PHARMA | FRANCE | Generics / Labs |
| 04/2015 | ASTORG | METROLOGIC GROUP | FRANCE | Supply Chain & Ops |
| 12/2013 | ASTORG | KERNEOS | FRANCE | Construction Materials |
| 11/2007 | ASTORG | TRESCAL | FRANCE | TIC (Testing, Inspection, Certification) |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 10/2013 | ARDIAN | LABORATOIRES ANIOS | FRANCE | Medical Consumables |
| 07/2013 | CHARTERHOUSE | DOC GENERICI | ITALY | Generics / Labs |
| 06/2013 | BC PARTNERS | ANTELLIQ | FRANCE | Animal Health |
| 06/2013 | EURAZEO | PÉTERS SURGICAL | FRANCE | Medical Consumables |
| 01/2013 | ELITECH GROUP | VITAL DIAGNOSTICS | UNITED STATES | Diagnostic Equipment |
| 08/2012 | BC PARTNERS | AENOVA GROUP | GERMANY | CDMO |
| 05/2011 | AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIA | LAGARRIGUE | FRANCE | Implants & Prosthetics |
| 09/2010 | SPARRING CAPITAL | IMV TECHNOLOGIES | FRANCE | R&D Biotech |
| 09/2009 | THE CARLYLE GROUP | MARLE GROUP | FRANCE | Implants & Prosthetics |
| 01/2006 | EDMOND DE ROTHSCHILD CAPITAL PARTNERS | ACTEON | FRANCE | Medical Devices |
REFERENCES
Valuation range: EV €300–700M
Revenue range: €100–200M
EBITDA range: €25–50M
EV/Revenue range: 1x - 3x
EV/EBITDA range: 10x - 18x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Ethypharm by Astorg are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: ethypharm
FAQ
What transaction does this page cover?
How was the acquisition of Ethypharm by Astorg valued, and what multiples were paid?
What were Ethypharm’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?